ER-4004

ER-4004 is a generic small-molecule formulation developed by SigmaPharm Laboratories. It is an extended-release (ER) drug candidate that has been submitted for regulatory approval via an Abbreviated New Drug Application (ANDA). The formulation leverages SigmaPharm's proprietary drug delivery technologies to provide a controlled release of the active pharmaceutical ingredient, intended to improve patient compliance or therapeutic outcomes compared to immediate-release versions. As a generic product, ER-4004 is designed to be bioequivalent to a branded reference drug. While the specific active ingredient is not publicly identified in the company's high-level pipeline summaries, the 'ER' designation confirms its status as an extended-release product within SigmaPharm's specialized portfolio of complex generics.